γ-heavy chain disease review of 23 cases

Dietlind L. Wahner-Roedler, Thomas Elmer Witzig, Laura L. Loehrer, Robert A. Kyle

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We report the cases of 23 patients with γ-heavy chain disease seen at our institution (8 patients previously reported, 15 new patients). There were 15 women and 8 men; the median age at diagnosis was 68 years (range, 42-87 yr). Sixteen patients had an associated lymphoplasma cell proliferative disorder, 3 had a lymphoplasma cell proliferative disorder and an autoimmune disorder, another 3 had an autoimmune disorder only, and 1 had no underlying disease. The lymphoplasma cell proliferative disorder was disseminated in 10 patients and localized in 6. Patients with localized lymphoplasma cell proliferative disorder included 3 with plasmacytoma (1 tongue, 1 submandibular area, and 1 thyroid), 2 with lymphoplasma cell proliferative disorder involving the bone marrow only, and 1 with amyloid of the skin. At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1. A monoclonal spike on serum protein electrophoresis was documented in 19 patients. γ-Heavy chain was documented by immunofixation in the serum of all patients; 2 had an additional immunoglobulin M-λ. γ-Heavy chain was present in the urine in 19 of 22 patients. Sixteen patients were treated for lymphoplasma cell proliferative disorder or autoimmune disorder (14 with chemotherapy, 1 splenectomy, and 1 thyroidectomy followed by radiation therapy). For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment. Of the 16 patients treated, 6 had a complete clinical response (in 2, γ-heavy chain disappeared; in 2, γ-heavy chain persisted; and for 2, no serologic follow-up was available); in 10 patients, clinical disease persisted (in 3, γ-heavy chain disappeared; in 6, it persisted; and for 1, no serologic follow-up was available). Of 7 patients not treated, 2 died within 5 months; 1 died after 15 months; 2 had no clinical disease at latest follow-up, although γ-heavy chain persisted; and 2 had no change in clinical and serologic status. The median duration of follow-up was 33 months (range, 1-261 mo). Median survival was 7.4 years.

Original languageEnglish (US)
Pages (from-to)236-250
Number of pages15
JournalMedicine
Volume82
Issue number4
DOIs
StatePublished - Jul 2003

Fingerprint

Heavy Chain Disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wahner-Roedler, D. L., Witzig, T. E., Loehrer, L. L., & Kyle, R. A. (2003). γ-heavy chain disease review of 23 cases. Medicine, 82(4), 236-250. https://doi.org/10.1097/00005792-200307000-00002

γ-heavy chain disease review of 23 cases. / Wahner-Roedler, Dietlind L.; Witzig, Thomas Elmer; Loehrer, Laura L.; Kyle, Robert A.

In: Medicine, Vol. 82, No. 4, 07.2003, p. 236-250.

Research output: Contribution to journalArticle

Wahner-Roedler, DL, Witzig, TE, Loehrer, LL & Kyle, RA 2003, 'γ-heavy chain disease review of 23 cases', Medicine, vol. 82, no. 4, pp. 236-250. https://doi.org/10.1097/00005792-200307000-00002
Wahner-Roedler, Dietlind L. ; Witzig, Thomas Elmer ; Loehrer, Laura L. ; Kyle, Robert A. / γ-heavy chain disease review of 23 cases. In: Medicine. 2003 ; Vol. 82, No. 4. pp. 236-250.
@article{fb5d5265dd66415a9460e62bd6a7e964,
title = "γ-heavy chain disease review of 23 cases",
abstract = "We report the cases of 23 patients with γ-heavy chain disease seen at our institution (8 patients previously reported, 15 new patients). There were 15 women and 8 men; the median age at diagnosis was 68 years (range, 42-87 yr). Sixteen patients had an associated lymphoplasma cell proliferative disorder, 3 had a lymphoplasma cell proliferative disorder and an autoimmune disorder, another 3 had an autoimmune disorder only, and 1 had no underlying disease. The lymphoplasma cell proliferative disorder was disseminated in 10 patients and localized in 6. Patients with localized lymphoplasma cell proliferative disorder included 3 with plasmacytoma (1 tongue, 1 submandibular area, and 1 thyroid), 2 with lymphoplasma cell proliferative disorder involving the bone marrow only, and 1 with amyloid of the skin. At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1. A monoclonal spike on serum protein electrophoresis was documented in 19 patients. γ-Heavy chain was documented by immunofixation in the serum of all patients; 2 had an additional immunoglobulin M-λ. γ-Heavy chain was present in the urine in 19 of 22 patients. Sixteen patients were treated for lymphoplasma cell proliferative disorder or autoimmune disorder (14 with chemotherapy, 1 splenectomy, and 1 thyroidectomy followed by radiation therapy). For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment. Of the 16 patients treated, 6 had a complete clinical response (in 2, γ-heavy chain disappeared; in 2, γ-heavy chain persisted; and for 2, no serologic follow-up was available); in 10 patients, clinical disease persisted (in 3, γ-heavy chain disappeared; in 6, it persisted; and for 1, no serologic follow-up was available). Of 7 patients not treated, 2 died within 5 months; 1 died after 15 months; 2 had no clinical disease at latest follow-up, although γ-heavy chain persisted; and 2 had no change in clinical and serologic status. The median duration of follow-up was 33 months (range, 1-261 mo). Median survival was 7.4 years.",
author = "Wahner-Roedler, {Dietlind L.} and Witzig, {Thomas Elmer} and Loehrer, {Laura L.} and Kyle, {Robert A.}",
year = "2003",
month = "7",
doi = "10.1097/00005792-200307000-00002",
language = "English (US)",
volume = "82",
pages = "236--250",
journal = "Medicine (United States)",
issn = "1357-3039",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - γ-heavy chain disease review of 23 cases

AU - Wahner-Roedler, Dietlind L.

AU - Witzig, Thomas Elmer

AU - Loehrer, Laura L.

AU - Kyle, Robert A.

PY - 2003/7

Y1 - 2003/7

N2 - We report the cases of 23 patients with γ-heavy chain disease seen at our institution (8 patients previously reported, 15 new patients). There were 15 women and 8 men; the median age at diagnosis was 68 years (range, 42-87 yr). Sixteen patients had an associated lymphoplasma cell proliferative disorder, 3 had a lymphoplasma cell proliferative disorder and an autoimmune disorder, another 3 had an autoimmune disorder only, and 1 had no underlying disease. The lymphoplasma cell proliferative disorder was disseminated in 10 patients and localized in 6. Patients with localized lymphoplasma cell proliferative disorder included 3 with plasmacytoma (1 tongue, 1 submandibular area, and 1 thyroid), 2 with lymphoplasma cell proliferative disorder involving the bone marrow only, and 1 with amyloid of the skin. At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1. A monoclonal spike on serum protein electrophoresis was documented in 19 patients. γ-Heavy chain was documented by immunofixation in the serum of all patients; 2 had an additional immunoglobulin M-λ. γ-Heavy chain was present in the urine in 19 of 22 patients. Sixteen patients were treated for lymphoplasma cell proliferative disorder or autoimmune disorder (14 with chemotherapy, 1 splenectomy, and 1 thyroidectomy followed by radiation therapy). For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment. Of the 16 patients treated, 6 had a complete clinical response (in 2, γ-heavy chain disappeared; in 2, γ-heavy chain persisted; and for 2, no serologic follow-up was available); in 10 patients, clinical disease persisted (in 3, γ-heavy chain disappeared; in 6, it persisted; and for 1, no serologic follow-up was available). Of 7 patients not treated, 2 died within 5 months; 1 died after 15 months; 2 had no clinical disease at latest follow-up, although γ-heavy chain persisted; and 2 had no change in clinical and serologic status. The median duration of follow-up was 33 months (range, 1-261 mo). Median survival was 7.4 years.

AB - We report the cases of 23 patients with γ-heavy chain disease seen at our institution (8 patients previously reported, 15 new patients). There were 15 women and 8 men; the median age at diagnosis was 68 years (range, 42-87 yr). Sixteen patients had an associated lymphoplasma cell proliferative disorder, 3 had a lymphoplasma cell proliferative disorder and an autoimmune disorder, another 3 had an autoimmune disorder only, and 1 had no underlying disease. The lymphoplasma cell proliferative disorder was disseminated in 10 patients and localized in 6. Patients with localized lymphoplasma cell proliferative disorder included 3 with plasmacytoma (1 tongue, 1 submandibular area, and 1 thyroid), 2 with lymphoplasma cell proliferative disorder involving the bone marrow only, and 1 with amyloid of the skin. At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1. A monoclonal spike on serum protein electrophoresis was documented in 19 patients. γ-Heavy chain was documented by immunofixation in the serum of all patients; 2 had an additional immunoglobulin M-λ. γ-Heavy chain was present in the urine in 19 of 22 patients. Sixteen patients were treated for lymphoplasma cell proliferative disorder or autoimmune disorder (14 with chemotherapy, 1 splenectomy, and 1 thyroidectomy followed by radiation therapy). For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment. Of the 16 patients treated, 6 had a complete clinical response (in 2, γ-heavy chain disappeared; in 2, γ-heavy chain persisted; and for 2, no serologic follow-up was available); in 10 patients, clinical disease persisted (in 3, γ-heavy chain disappeared; in 6, it persisted; and for 1, no serologic follow-up was available). Of 7 patients not treated, 2 died within 5 months; 1 died after 15 months; 2 had no clinical disease at latest follow-up, although γ-heavy chain persisted; and 2 had no change in clinical and serologic status. The median duration of follow-up was 33 months (range, 1-261 mo). Median survival was 7.4 years.

UR - http://www.scopus.com/inward/record.url?scp=0037823442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037823442&partnerID=8YFLogxK

U2 - 10.1097/00005792-200307000-00002

DO - 10.1097/00005792-200307000-00002

M3 - Article

VL - 82

SP - 236

EP - 250

JO - Medicine (United States)

JF - Medicine (United States)

SN - 1357-3039

IS - 4

ER -